A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy as a possible treatment for thyroid
cancer. A targeted therapy is a type of treatment that uses drugs or other substances to
identify and attack specific types of cancer cells with less harm to normal cells.
- The name of the study intervention involved in this study is regorafenib.